Operational Costs Compared: SG&A Analysis of argenx SE and Bio-Techne Corporation

A Comparative Analysis of SG&A Expenses in Biotech Giants

In the dynamic world of biotechnology, operational efficiency is key to sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Bio-Techne Corporation and argenx SE, from 2014 to 2023. Over this period, Bio-Techne's SG&A expenses have shown a steady increase, peaking at approximately 396 million in 2023, marking a 550% rise from 2014. Meanwhile, argenx SE has experienced a more dramatic surge, with expenses skyrocketing by over 16,000% from 2014 to 2023, reaching around 710 million. This stark contrast highlights argenx SE's aggressive expansion strategy. However, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to evolve, monitoring their operational costs will provide valuable insights into their strategic directions.